Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Minerva Neuroscie (NERV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 342,938
  • Shares Outstanding, K 38,750
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,520 K
  • 36-Month Beta 1.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.83

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.00 +10.63%
on 06/06/18
9.25 -4.32%
on 06/19/18
+0.85 (+10.63%)
since 05/22/18
3-Month
5.80 +52.59%
on 05/08/18
9.25 -4.32%
on 06/19/18
+2.35 (+36.15%)
since 03/22/18
52-Week
4.80 +84.38%
on 11/14/17
10.15 -12.81%
on 07/05/17
-0.70 (-7.33%)
since 06/22/17

Most Recent Stories

More News
Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced...

NERV : 8.85 (+1.72%)
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...

WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system...

NERV : 8.85 (+1.72%)
Dutch Company Xenikos Secures USD 30 Million in Series B Financing

AMGN : 185.15 (-0.45%)
CELGZ : 0.39 (-2.50%)
BMY : 55.14 (+2.22%)
NERV : 8.85 (+1.72%)
MIN-101 (Minerva Neurosciences/Mitsubishi Tanabe) Drug Overview 2017/2018-2026: A Novel Antagonist of the Sigma-2 and Serotonin 5-HT2A Receptors - ResearchAndMarkets.com

The "Drug Overview: MIN-101" report has been added to ResearchAndMarkets.com's offering.

NERV : 8.85 (+1.72%)
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business...

NERV : 8.85 (+1.72%)
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will...

NERV : 8.85 (+1.72%)
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder

WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...

NERV : 8.85 (+1.72%)
Detailed Research: Economic Perspectives on Altisource Residential, Sykes Enterprises, Gibraltar Industries, Silicon Laboratories, TC PipeLines, LP, and Minerva Neurosciences -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Altisource Residential Corporation...

TCP : 26.52 (+1.41%)
ROCK : 38.80 (-1.77%)
SYKE : 29.02 (-1.16%)
SLAB : 103.75 (-1.28%)
RESI : 10.89 (+0.18%)
NERV : 8.85 (+1.72%)
Will Minerva Neurosciences (NERV) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV).

NERV : 8.85 (+1.72%)
Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22

Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a Key Opinion...

NERV : 8.85 (+1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade NERV with:

Business Summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive...

See More

Key Turning Points

2nd Resistance Point 9.08
1st Resistance Point 8.97
Last Price 8.85
1st Support Level 8.67
2nd Support Level 8.48

See More

52-Week High 10.15
Last Price 8.85
Fibonacci 61.8% 8.11
Fibonacci 50% 7.47
Fibonacci 38.2% 6.84
52-Week Low 4.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar